Product Details

The RMP1-14-CP151 monoclonal antibody is a chimeric version of the original RMP1-14 antibody. The variable domain sequences are identical to the original RMP1-14 but the constant region sequences have been switched from rat IgG2a to mouse IgG2a. The RMP1-14-CP151 antibody also contains a D265A mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. RMP1-14-CP151 reacts with mouse PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily. PD-1 is transiently expressed on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. PD-1 expression declines after successful elimination of antigen. Additionally, Pdcd1 mRNA is expressed in developing B lymphocytes during the pro-B-cell stage. PD-1’s structure includes a ITIM (immunoreceptor tyrosine-based inhibitory motif) suggesting that PD-1 negatively regulates TCR signals. PD-1 signals via binding its two ligands, PD-L1 and PD-L2 both members of the B7 family. Upon ligand binding, PD-1 signaling inhibits T-cell activation, leading to reduced proliferation, cytokine production, and T-cell death. Additionally, PD-1 is known to play key roles in peripheral tolerance and prevention of autoimmune disease in mice as PD-1 knockout animals show dilated cardiomyopathy, splenomegaly, and loss of peripheral tolerance. Induced PD-L1 expression is common in many tumors including squamous cell carcinoma, colon adenocarcinoma, and breast adenocarcinoma. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. In mouse models of melanoma, tumor growth can be transiently arrested via treatment with antibodies which block the interaction between PD-L1 and its receptor PD-1. For these reasons anti-PD-1 mediated immunotherapies are currently being explored as cancer treatments.

?

BioXCell?RecombiMAb小鼠PD-1(CD279)抗體(D265A)：

RMP1-14-CP151單克隆抗體是原始RMP1-14抗體的嵌合版本?？勺兘Y(jié)構(gòu)域序列與原始RMP1-14相同，但恒定區(qū)域序列已從大鼠IgG2a切換到小鼠IgG2a。RMP1-14-CP151抗體在Fc片段中還含有D265A突變，使其無法與內(nèi)源性Fcγ受體結(jié)合。RMP1-14-CP151與小鼠PD-1（程序性死亡-1）反應(yīng)，也稱為CD279。PD-1是由Pdcd50基因編碼的55-1 kDa細(xì)胞表面受體，屬于Ig超家族的CD28家族。PD-1在CD4和CD8胸腺細(xì)胞以及活化的T和B淋巴細(xì)胞和骨髓細(xì)胞上短暫表達(dá)。PD-1在成功消除抗原后表達(dá)下降。

?

BioXCell艾美捷RecombiMAb小鼠PD-1(CD279)抗體(D265A)規(guī)格：

# ?BXC-CP151

Isotype?Mouse IgG2a, κ

Recommended Isotype Control(s)?RecombiMAb mouse IgG2a (D265A) isotype control, anti-hen egg lysozyme

Recommended Dilution Buffer?InVivoPure pH 7.0 Dilution Buffer

Mutations?D265A

Immunogen?Syrian Hamster BKH cells transfected with mouse PD-1 cDNA

Reported Applications?in vivo blocking of PD-1/PD-L signaling*

*Reported for the original rat IgG2a RMP1-14 antibody

Formulation?PBS, pH 7.0

Contains no stabilizers or preservatives

Endotoxin?<1EU/mg (<0.001EU/μg)

Determined by LAL gel clotting assay

Aggregation?<5%

Determined by DLS

Purity?>95%

Determined by SDS-PAGE

Sterility?0.2 μM filtered

Production?Purified from CHO cell supernatant in an animal free facility

Purification?Protein G

RRID?AB_2927525

Molecular Weight?150 kDa

Murine Pathogen Tests?Ectromelia/Mousepox Virus: Negative

Hantavirus: Negative

K Virus: Negative

Lactate Dehydrogenase-Elevating Virus: Negative

Lymphocytic Choriomeningitis virus: Negative

Mouse Adenovirus: Negative

Mouse Cytomegalovirus: Negative

Mouse Hepatitis Virus: Negative

Mouse Minute Virus: Negative

Mouse Norovirus: Negative

Mouse Parvovirus: Negative

Mouse Rotavirus: Negative

Mycoplasma Pulmonis: Negative

Pneumonia Virus of Mice: Negative

Polyoma Virus: Negative

Reovirus Screen: Negative

Sendai Virus: Negative

Theiler’s Murine Encephalomyelitis: Negative

Storage?The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.

同種型?小鼠IgG2a， κ

推薦的同種型對照?RecombiMAb小鼠IgG2a（D265A）同種型對照，抗母蛋溶菌酶

推薦的稀釋緩沖液?體內(nèi)純?pH 7.0 稀釋緩沖液

突變?D265A

免疫原?用小鼠PD-1 cDNA轉(zhuǎn)染的敘利亞倉鼠BKH細(xì)胞

報告的應(yīng)用程序?體內(nèi)阻斷PD-1/PD-L信號傳導(dǎo)**

報道了原始大鼠IgG2a RMP1-14抗體

配方?PBS，pH 7.0

不含穩(wěn)定劑或防腐劑

內(nèi)毒素?<1EU/mg （<0.001EU/μg）

通過LAL凝膠凝血測定法測定

集合體?<5%

由?DLS 確定

純度?>95%

由?SDS-PAGE 決定

無?菌?0.2 μM 過濾

生產(chǎn)?從無動物設(shè)施中的CHO細(xì)胞上清液中純化

純化?蛋白?G

里德?AB_2927525

分子量?150 千達(dá)

鼠病原體檢測?外切粒菌/鼠痘病毒： 陰性 漢坦病毒： 陰性 K 病毒： 陰性乳酸脫氫酶升高病毒： 陰性 淋巴細(xì)胞性脈絡(luò)叢腦膜炎病毒： 陰性小鼠腺病毒： 陰性小鼠巨細(xì)胞病毒： 陰性小鼠肝炎病毒： 陰性小鼠分鐘病毒： 陰性小鼠諾如病毒： 陰性小鼠細(xì)小病毒： 陰性

小鼠輪狀病毒：肺支原體陰性：陰性?小鼠肺炎病毒：陰性?多瘤病毒：陰性呼腸孤病毒篩查：陰性?仙臺病毒：陰性?泰勒鼠腦脊髓炎：陰性

存儲?抗體溶液應(yīng)以4°C的儲備濃度儲存。 不要凍結(jié)。